In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $1.46 up 14.06% from its previous closing price of $1.28. In other words, the price has increased by $14.06 from its previous closing price. On the day, 1.26 million shares were traded. IRWD stock price reached its highest trading level at $1.46 during the session, while it also had its lowest trading level at $1.2791.
Ratios:
For a deeper understanding of Ironwood Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.92. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 0.82.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’25 when Gaskins Tammi L sold 1,316 shares for $0.84 per share. The transaction valued at 1,105 led to the insider holds 241,280 shares of the business.
John Minardo sold 7,754 shares of IRWD for $6,513 on Aug 11 ’25. The Chief Legal Officer now owns 400,378 shares after completing the transaction at $0.84 per share. On Aug 11 ’25, another insider, Martini Gregory S., who serves as the Chief Financial Officer of the company, sold 1,265 shares for $0.84 each. As a result, the insider received 1,063 and left with 182,545 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 237153840 and an Enterprise Value of 742970816. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 0.77. Its current Enterprise Value per Revenue stands at 2.408 whereas that against EBITDA is 7.931.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.30, which has changed by -0.6604651 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.13, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of. The Stock is 43.83%, while the 200-Day Moving Average is calculated to be -12.08%.
Shares Statistics:
For the past three months, IRWD has traded an average of 1.49M shares per day and 1182860 over the past ten days. A total of 162.43M shares are outstanding, with a floating share count of 156.37M. Insiders hold about 3.74% of the company’s shares, while institutions hold 90.48% stake in the company. Shares short for IRWD as of 1756425600 were 6063890 with a Short Ratio of 4.07, compared to 1753920000 on 5382745. Therefore, it implies a Short% of Shares Outstanding of 6063890 and a Short% of Float of 5.6599997.
Earnings Estimates
. The Stock of Ironwood Pharmaceuticals Inc (IRWD) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.11, with high estimates of $0.11 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.21 and $0.21 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.21, with 3.0 analysts recommending between $0.4 and $0.0.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $74.22M this quarter.It ranges from a high estimate of $83.4M to a low estimate of $68.4M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $91.59MFor the next quarter, 5 analysts are estimating revenue of $76.4M. There is a high estimate of $84M for the next quarter, whereas the lowest estimate is $70M.
A total of 5 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $275.2M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $272.3M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $258.84M in the next fiscal year. The high estimate is $285M and the low estimate is $225.8M.
